Add like
Add dislike
Add to saved papers

Radiological evaluation of kyphoplasty with an intravertebral expander after osteoporotic vertebral fracture.

Spinal deformities due to osteoporotic vertebral compression fractures can be reduced by balloon kyphoplasty, but the correction may be partly lost when the balloon is deflated. The present study aimed to evaluate an intravertebral expander developed to reduce and maintain vertebral body height while cement is injected to correct spinal deformities due to osteoporotic vertebral fractures. The study included 31 osteoporotic vertebral body fractures in 31 patients, classified as A1 according to the AO classification, who underwent kyphoplasty using an intravertebral expander. The kyphosis angle was significantly corrected from 13.4 degrees prior to kyphoplasty to 10.8 degrees (p < 0.01) after surgery, but this correction was lost at 12 months (13.3 degrees). The correction of the kyphosis angle best correlated with the pre-operative mobility of the fracture (r = 0.59, p < 0.01), and the loss of the kyphosis improvement correlated with the amount of correction (r = 0.49, p = 0.01). All patients, except for six with adjacent vertebral fractures, experienced significant pain reduction (VAS 8.7 pre-operatively and 2.0 at 12 months; p < 0.01), and the pain was not affected by the correction of the spinal deformity or the loss of correction in the follow-up period. These results suggest that the mobility of the fracture mainly determines the extent of deformity correction rather the device used for reduction, and greater corrections are at increased risk for losing the improvement. This article is protected by copyright. All rights reserved.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app